Baiyunshan (00874): Subsidiary's Pharmaceutical Production License Amended

Stock News
Feb 02

Baiyunshan (00874) announced that its subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., has received a Pharmaceutical Production License approved and issued by the Guangdong Provincial Medical Products Administration. The license approves Qixing Pharmaceutical's request to add a new entrusted production address for the manufacturing of Xuhanting Granules (Sugar-Free Type), which it has outsourced to the Baiyunshan Pharmaceutical General Factory, a subsidiary of Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., based on the original outsourcing production address. This addition of a new entrusted production address for the manufacturing of Xuhanting Granules (Sugar-Free Type) by Qixing Pharmaceutical, building upon the original outsourcing arrangement with Baiyunshan Pharmaceutical General Factory, is beneficial for increasing production capacity, enhancing manufacturing efficiency, and meeting market demand. The acquisition of this Pharmaceutical Production License is not expected to have a material impact on the company's current period performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10